Specialists from the Center for Pharmaceutical Product Safety State Institution and Jelena Volperte, Director of Regulatory Affairs at the Latvian company Olpha, held an online meeting on September 7 to discuss bilateral cooperation in clinical trials and medicine registration standards.
Cooperation Priorities and Training Plans
During the online session, participants focused on two specific areas proposed by the Center. Officials reviewed modern international approaches and standards governing clinical trials regulation. They also examined methods to improve the quality expertise of medicine registration dossiers following the requirements of ICH CTD Module 3.
Volperte expressed strong interest from the Latvian firm in collaborating with the Uzbek side across these domains. Furthermore, she announced the company’s readiness to conduct targeted seminars and practical training sessions tailored for the Center’s specialists. Both teams exchanged direct contact information for responsible personnel. They agreed that once the Uzbek side submits preferred dates, they will finalize the program, format, duration, and logistical arrangements for the upcoming sessions.
Did You Know? Headquartered in the Latvian city of Olaine, “Olpha” JSC has operated in the pharmaceutical sector since 1972 and currently employs more than 850 specialists.
Company Background and Operational Scope
The partnering firm brings decades of manufacturing experience to the collaborative initiative. Operating out of Olaine, the enterprise produces over 60 dosage forms, 25 active pharmaceutical ingredients, and more than 20 types of intermediate products. Its commercial and scientific footprint spans multiple complex therapeutic sectors, including cardiology, pulmonology, neurology, psychiatry, endocrinology, and oncology.
Frequently Asked Questions
Who participated in the online meeting on September 7?
The meeting included specialists from the Center for Pharmaceutical Product Safety State Institution alongside Jelena Volperte, Director of Regulatory Affairs at the Latvian company Olpha.
What specific topics were discussed during the session?
The participants discussed studying modern international approaches and standards in clinical trials regulation, as well as improving the quality expertise of medicine registration dossiers under ICH CTD Module 3 requirements.
What is the background of the partnering company?
“Olpha” JSC is a pharmaceutical company operating since 1972 with headquarters in Olaine, Latvia. The firm employs over 850 specialists and manufactures more than 60 dosage forms, 25 active pharmaceutical ingredients, and over 20 types of intermediate products across several therapeutic areas.
How will the upcoming training sessions be organized?
The Uzbek side will submit tentatively agreed preferred dates, after which the parties will determine the program, format, duration, and organizational matters to arrange the training.
What operational areas does the Latvian company cover?
The company operates in therapeutic areas such as cardiology, pulmonology, neurology, psychiatry, endocrinology, and oncology, among other fields.
Related reading